A Breakthrough in Personalised Psychiatry

Following its involvement in the Cardiff Capital Region (CCR) Academic-Industry Partnerships (AIP) Programme, Cardiff-based MeOmics has been able to develop a revolutionary new platform that interprets complex neurological data to transform psychiatric drug development.

The service—currently pre-launch—introduces a world-first approach to predicting patient responses to medication, setting the stage for personalised treatments, smarter clinical trials, and stronger regional innovation. The project is already driving new opportunities in precision medicine, commercial partnerships, and sustainable growth.

The Company

MeOmics is an ambitious biotech company pioneering the use of human-derived neuronal cell models and AI-driven data analysis to improve drug development and mental healthcare. Its upcoming product—the MeOmics Precision Psychiatry Drug Screening Platform—aims to transform how researchers and pharmaceutical companies screen, validate, and personalise psychiatric treatments.

The Challenge

Until now, no one had analysed neurological data from computer model tests in this way. Understanding how individual neuron samples respond to medication and evaluating their health in real time presented a scientific and technical challenge that had never been addressed.

For MeOmics, the task was to make sense of this untapped data, developing a way to turn raw neural signals into clear, actionable insights about drug efficacy and patient response. It required not just a new product, but an entirely new method of interpreting neurological behaviour.

The Solution

With bespoke support from CEMET (USW’s Centre of Excellence in Mobile and Emerging Technologies), MeOmics tackled this challenge head-on. The collaboration helped the team design and implement advanced models and algorithms capable of decoding complex neuron activity.

Together, they built a new analytical framework to understand and predict how different patients might respond to neuro-active drugs—creating a breakthrough that could change the course of psychiatric care.

The result is a powerful, pre-launch platform that combines AI, automation, and human cell modelling in one scalable solution.

The Results

The impact of this project is already being felt:

• Groundbreaking new capability: MeOmics now has a proprietary service that decodes previously inaccessible neurological data—unlocking patterns in neuron behaviour that predict patient responses to psychiatric medications.
• Commercial momentum: With £450k in pre-seed investment secured (including backing from the Development Bank of Wales), MeOmics is preparing to launch pilot studies and sign early contracts with pharmacy and contact research organisation
• Path to market: In the next 12 months, MeOmics will expand its patient-derived neuron cell database, refine its platform, and commercialise its high-throughput drug screening service—reducing trial risks and costs for pharma clients.
• Social impact: The platform’s potential to improve treatment outcomes—especially for underserved populations—supports better mental healthcare and aligns with global moves toward personalised medicine.
• Regional growth: The project supports high-value job creation, advances the CCR’s medtech strategy, and strengthens South Wales’ reputation as a centre of life sciences innovation.

This collaboration shows what’s possible when bold biotech meets the right expertise. By building something entirely new, MeOmics is opening a frontier in precision psychiatry—bringing better treatments closer to the people who need them most.